Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The company expects net sales to increase due to growth in イズカーゴ sales volume, sales of its core products remaining at the same level as in the current fiscal year, and continued efforts in its licensing business. It plans to make proactive R&D investments to achieve further growth in the future, with research and development expenses expected to reach ¥19.3 billion, up 15.7% from the current fiscal year.
Loss on disposal of fixed assets: ¥32 million
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥45,700 million（＋13.3％） |
| Operating profit | Not disclosed → ¥1,100 million（＋98.2％） |
| Ordinary income | Not disclosed → ¥500 million（△57.1％） |
| Profit attributable to owners of the parent | Not disclosed → ¥200 million（△90.8％） |
| Net income per share | Not disclosed → 1.64 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Net sales: ¥40,319 million; operating profit: ¥555 million; ordinary profit: ¥1,165 million; net income attributable to owners of the parent: ¥2,178 million (fiscal year ended March 2026) |
| Reason for the revision | The company expects net sales to increase due to growth in イズカーゴ sales volume, sales of its core products remaining at the same level as in the current fiscal year, and continued efforts in its licensing business. It plans to make proactive R&D investments to achieve further growth in the future, with research and development expenses expected to reach ¥19.3 billion, up 15.7% from the current fiscal year. |
| Details and amount of extraordinary loss | Loss on disposal of fixed assets: ¥32 million |
| Dividend forecast revision | For the fiscal year ending March 2027, a dividend of ¥20 per share is planned, comprising an interim dividend of ¥10 and a year-end dividend of ¥10. Whether this represents a revision is not specified. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended March 2026, strong performance by the イズカーゴ product and increases in product sales and contract fee income drove higher revenue, while グロウジェクト product sales declined following a drug price revision, and research and development expenses increased due to contract upfront fees and other costs associated with the introduction of Givinostat. For the fiscal year ending March 2027, the company expects sales volume growth for イズカーゴ and the continuation of its licensing business. To step up R&D investment for future growth, research and development expenses are expected to reach ¥19.3 billion.